Search company, investor...

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Debt | Alive

Total Raised


Last Raised

$500K | 4 yrs ago

About Mirata BioPharma

Mirata BioPharma focuses on new immuno-oncology fusion protein technology. Its initial focus is to develop biopharmaceutical compounds licensed from the research development foundation, a nonprofit supporting organization of the Clayton Foundation for Research. The Clayton Foundation is a nonprofit medical research organization.

Mirata BioPharma Headquarters Location

2450 Holcombe Blvd Suite J

Houston, Texas, 77021,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Mirata BioPharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Mirata BioPharma is included in 2 Expert Collections, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.



3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

Latest Mirata BioPharma News

Strategia Holdings Announces Strategic Partnership Alliance with JS InnoPharm Shanghai for Global Drug Development

Aug 27, 2018

“We are very excited about this strategic partnership with JS InnoPharm in Shanghai. By combining the strengths of JS InnoPharm with their drug discovery expertise and China network to Strategia Holdings, LLC, we are creating a new, efficient, streamlined model for global drug development,” said Dr. Keizo Koya, CEO and Founder of Strategia. “This is an innovative and unique collaboration that will translate the highest-quality science into proven clinical success in an efficient and agile manner while enhancing the competitive position of both companies in the ever-increasing challenging environment of clinical drug development. The ultimate goal of this partnership is to effectively deliver new therapeutic approaches to patients worldwide.” The Strategia Holdings group currently consists of three biopharmaceutical companies; Spirita Oncology, LLC, Mirata BioPharma, LLC, and Strategia Pharmaceuticals, LLC. All three organizations will work closely together with JS InnoPharm under the Strategic Partnership Alliance. “JS InnoPharm is keen on collaborating with Strategia to establish long-term commitments to accelerate global drug development with us,” said Dr. Jintao Zhang, CEO of JS InnoPharm. “We believe in the power of China and the US coming together and crafting solutions to enhance efficiencies and achieve faster drug development timelines with higher success rates. This partnership allows the organizations to work closely together in a collaborative effort to reach those goals.” About Strategia Strategia Holdings, LLC, is based in the U.S. and oversees three biotech companies; Spirita Oncology, LLC, Mirata BioPharma, LLC, and Strategia Pharmaceuticals, LLC. Spirita focuses on oncology drug development in the US with E6201, a MEK1 inhibitor, as their flagship candidate focused on melanoma brain metastases. Mirata is a pre-clinical stage immuno-oncology company based on a Targeted Granzyme B Immunotherapy (TGI) platform. Strategia Pharmaceuticals was established in 2012 consisting of oncology pharma and biotech drug development veterans, and is a strategic consulting company to assist pharma and biotech clients develop their oncology portfolios with greater expertise, more efficiently, more rapidly, translating into lower overall cost to market. View source version on MEDIA:

  • When was Mirata BioPharma founded?

    Mirata BioPharma was founded in 2017.

  • Where is Mirata BioPharma's headquarters?

    Mirata BioPharma's headquarters is located at 2450 Holcombe Blvd, Houston.

  • What is Mirata BioPharma's latest funding round?

    Mirata BioPharma's latest funding round is Debt.

  • How much did Mirata BioPharma raise?

    Mirata BioPharma raised a total of $500K.

  • Who are the investors of Mirata BioPharma?

    Investors of Mirata BioPharma include JLabs.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.